X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Innovation comes in many forms, including new and expanded uses of existing medicines

By Emma Van Hook  |    January 29, 2018
2017 was a record-breaking year for new drug approvals, with the U.S. Food and Drug Administration (FDA) approving 56 new drugs and biologics. But the innovation did not stop there. As the FDA...   Read More

ICYMI: Why 2017 medicine approvals matter

By Andrew Powaleny  |    January 12, 2018
This week, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) released its 2017 New Drug Therapy Approvals report. Last year marked an extraordinary...   Read More

New surveys find payers and providers want more data from biopharmaceutical companies

By Joe Vandigo  |    December 6, 2017
Both payers and providers are interested in additional information from biopharmaceutical companies about prescription medicines – including information about pipeline medicines and unapproved...   Read More

Supporting opportunities for enhanced competition in the marketplace

By Andrew Powaleny  |    November 22, 2017
Promoting competition is an important focus for the biopharmaceutical industry. Since 1984, the Hatch-Waxman Act has fostered robust competition through the timely entry of generic medicines into...   Read More

VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria

By Holly Campbell  |    October 12, 2017
PhRMA president and CEO Stephen J. Ubl joined Fox Business’ Maria Bartiromo on “Mornings with Maria” today to discuss bold steps the biopharmaceutical industry has taken in the last few months as...   Read More

Opportunities to build upon enhanced competition for medicines in the marketplace

By David Korn  |    July 27, 2017
Last week, I presented at the U.S Food and Drug Administration’s (FDA) public meeting on the Hatch-Waxman Amendments to discuss the balance between encouraging innovation in biopharmaceutical...   Read More

Why reauthorization of PDUFA matters

By Andrew Powaleny  |    July 13, 2017
Last night, the Prescription Drug User Fee Act (PDUFA), was reauthorized by the House of Representatives. PDUFA provides the U.S. Food and Drug Administration (FDA) with necessary resources to...   Read More

A critical opportunity to prevent prescription drug abuse

By Anne McDonald Pritchett, PhD  |    June 2, 2017
U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb recently cited addressing the opioid crisis as his highest priority. As someone who has spent the bulk of my career focused on...   Read More

Guest Post: The importance of a modern FDA in drug discovery

By Guest Contributor  |    March 22, 2017
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Building on the promise of personalized medicine

By Andrew Powaleny  |    November 16, 2016
PhRMA’s member companies are on the leading edge of personalized medicine development– an area that is transforming health care, improving patient outcomes and creating health system efficiencies....   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates